| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Pre-clinical data readout example | CNTY-813 type 1 diabetes | Pre-clinical | 21.5% Century Therapeutics (NASDAQ: IPSC) is advancing CNTY-813, its lead program targeting type 1 diabetes (T1D) through an innovative allogeneic induced pluripotent stem cell (iPSC)-derived beta islet cell therapy. Utilizing the proprietary Allo-Evasion 5.0 technology, CNTY-813 aims to facilitate durable insulin production and glycemic control without the need for systemic immunosuppression, thereby positioning itself as a potentially curative option in a therapeutic landscape that has primarily focused on symptomatic insulin management. The T1D market is significant, with an estimated global market size of $15 billion for insulin and related therapies as of 2024. This market is driven by approximately 8-10 million patients worldwide who require lifelong daily insulin injections, facing risks of hypoglycemia and complications such as neuropathy and retinopathy. The unmet need in this area is acute, as no approved therapies currently restore endogenous insulin production without immunosuppression. CNTY-813 is classified as first-in-class, offering a novel hypoimmunogenic iPSC islet approach that stands apart from existing treatments, including standard insulins like Humalog and insulin pumps, as well as near-term competitors. As of May 14, 2026, CNTY-813 remains in pre-clinical development, with no clinical trials initiated and no NCT numbers or enrollment data available. The anticipated IND submission is set for 2026, with initial Phase 1 clinical data expected in 2027, according to the company's financing announcement. Details regarding trial design, endpoints, and safety profiles have not yet been disclosed. Notably, CNTY-813 has not received any regulatory designations for T1D, including Fast Track, Orphan Drug, or Breakthrough Therapy designations. The competitive landscape for CNTY-813 includes Vertex's zimislecel (formerly VX-880), which is currently in Phase 3 and requires immunosuppression, as well as pre-clinical efforts from ViaCyte/Sandoz. There are currently no direct approved rivals for curative cell therapies in this space. Century Therapeutics has not yet achieved any FDA approvals, having previously focused on iPSC platforms, and its prior oncology assets encountered setbacks. However, the pivot to T1D leverages advancements in Allo-Evasion technology. Notably, there are no partnerships currently associated with this program. Precedents in the field inform the estimated probability of approval (PoA) for CNTY-813, which is set at 18-25%. Vertex's VX-880 has demonstrated proof-of-concept for insulin independence in a small Phase 1/2 trial, though it requires immunosuppression, underscoring the value and risk associated with immune evasion technology. Historical challenges with Sernova's Cell Pouch and islet transplants, which have shown limited durability, highlight the typical pre-clinical to approval odds for cell therapies in T1D and autoimmunity, generally ranging from 10-20%. The PoA for CNTY-813 reflects strong financing and execution signals that mitigate some modality risks, despite the absence of human data and Century's unproven status. Key risks associated with CNTY-813 include high technical challenges related to iPSC-derived islet engraftment, vascularization, and long-term function in humans. Additionally, there are concerns regarding potential immune evasion failures leading to rejection, manufacturing scalability, and consistency of potency for allogeneic cell therapy at a commercial scale. Upcoming catalysts include the IND submission in 2026 and initial Phase 1 clinical data in 2027. The investment thesis for CNTY-813 presents a high-risk, high-reward opportunity for a breakthrough in T1D treatment, warranting close monitoring of preclinical updates. Read More | Cell Therapies | Endocrine System | ||
Pre-clinical data readout example | CNTY-813 type 1 diabetes | Pre-clinical | 21.5% Century Therapeutics (NASDAQ: IPSC) is advancing CNTY-813, its lead program targeting type 1 diabetes (T1D) through an innovative allogeneic induced pluripotent stem cell (iPSC)-derived beta islet cell therapy. Utilizing the proprietary Allo-Evasion 5.0 technology, CNTY-813 aims to facilitate durable insulin production and glycemic control without the need for systemic immunosuppression, thereby positioning itself as a potentially curative option in a therapeutic landscape that has primarily focused on symptomatic insulin management. The T1D market is significant, with an estimated global market size of $15 billion for insulin and related therapies as of 2024. This market is driven by approximately 8-10 million patients worldwide who require lifelong daily insulin injections, facing risks of hypoglycemia and complications such as neuropathy and retinopathy. The unmet need in this area is acute, as no approved therapies currently restore endogenous insulin production without immunosuppression. CNTY-813 is classified as first-in-class, offering a novel hypoimmunogenic iPSC islet approach that stands apart from existing treatments, including standard insulins like Humalog and insulin pumps, as well as near-term competitors. As of May 14, 2026, CNTY-813 remains in pre-clinical development, with no clinical trials initiated and no NCT numbers or enrollment data available. The anticipated IND submission is set for 2026, with initial Phase 1 clinical data expected in 2027, according to the company's financing announcement. Details regarding trial design, endpoints, and safety profiles have not yet been disclosed. Notably, CNTY-813 has not received any regulatory designations for T1D, including Fast Track, Orphan Drug, or Breakthrough Therapy designations. The competitive landscape for CNTY-813 includes Vertex's zimislecel (formerly VX-880), which is currently in Phase 3 and requires immunosuppression, as well as pre-clinical efforts from ViaCyte/Sandoz. There are currently no direct approved rivals for curative cell therapies in this space. Century Therapeutics has not yet achieved any FDA approvals, having previously focused on iPSC platforms, and its prior oncology assets encountered setbacks. However, the pivot to T1D leverages advancements in Allo-Evasion technology. Notably, there are no partnerships currently associated with this program. Precedents in the field inform the estimated probability of approval (PoA) for CNTY-813, which is set at 18-25%. Vertex's VX-880 has demonstrated proof-of-concept for insulin independence in a small Phase 1/2 trial, though it requires immunosuppression, underscoring the value and risk associated with immune evasion technology. Historical challenges with Sernova's Cell Pouch and islet transplants, which have shown limited durability, highlight the typical pre-clinical to approval odds for cell therapies in T1D and autoimmunity, generally ranging from 10-20%. The PoA for CNTY-813 reflects strong financing and execution signals that mitigate some modality risks, despite the absence of human data and Century's unproven status. Key risks associated with CNTY-813 include high technical challenges related to iPSC-derived islet engraftment, vascularization, and long-term function in humans. Additionally, there are concerns regarding potential immune evasion failures leading to rejection, manufacturing scalability, and consistency of potency for allogeneic cell therapy at a commercial scale. Upcoming catalysts include the IND submission in 2026 and initial Phase 1 clinical data in 2027. The investment thesis for CNTY-813 presents a high-risk, high-reward opportunity for a breakthrough in T1D treatment, warranting close monitoring of preclinical updates. Read More | Cell Therapies | Endocrine System | ||
Pre-clinical data readout example | CNTY-813 type 1 diabetes | Pre-clinical | 21.5% Century Therapeutics (NASDAQ: IPSC) is advancing CNTY-813, its lead program targeting type 1 diabetes (T1D) through an innovative allogeneic induced pluripotent stem cell (iPSC)-derived beta islet cell therapy. Utilizing the proprietary Allo-Evasion 5.0 technology, CNTY-813 aims to facilitate durable insulin production and glycemic control without the need for systemic immunosuppression, thereby positioning itself as a potentially curative option in a therapeutic landscape that has primarily focused on symptomatic insulin management. The T1D market is significant, with an estimated global market size of $15 billion for insulin and related therapies as of 2024. This market is driven by approximately 8-10 million patients worldwide who require lifelong daily insulin injections, facing risks of hypoglycemia and complications such as neuropathy and retinopathy. The unmet need in this area is acute, as no approved therapies currently restore endogenous insulin production without immunosuppression. CNTY-813 is classified as first-in-class, offering a novel hypoimmunogenic iPSC islet approach that stands apart from existing treatments, including standard insulins like Humalog and insulin pumps, as well as near-term competitors. As of May 14, 2026, CNTY-813 remains in pre-clinical development, with no clinical trials initiated and no NCT numbers or enrollment data available. The anticipated IND submission is set for 2026, with initial Phase 1 clinical data expected in 2027, according to the company's financing announcement. Details regarding trial design, endpoints, and safety profiles have not yet been disclosed. Notably, CNTY-813 has not received any regulatory designations for T1D, including Fast Track, Orphan Drug, or Breakthrough Therapy designations. The competitive landscape for CNTY-813 includes Vertex's zimislecel (formerly VX-880), which is currently in Phase 3 and requires immunosuppression, as well as pre-clinical efforts from ViaCyte/Sandoz. There are currently no direct approved rivals for curative cell therapies in this space. Century Therapeutics has not yet achieved any FDA approvals, having previously focused on iPSC platforms, and its prior oncology assets encountered setbacks. However, the pivot to T1D leverages advancements in Allo-Evasion technology. Notably, there are no partnerships currently associated with this program. Precedents in the field inform the estimated probability of approval (PoA) for CNTY-813, which is set at 18-25%. Vertex's VX-880 has demonstrated proof-of-concept for insulin independence in a small Phase 1/2 trial, though it requires immunosuppression, underscoring the value and risk associated with immune evasion technology. Historical challenges with Sernova's Cell Pouch and islet transplants, which have shown limited durability, highlight the typical pre-clinical to approval odds for cell therapies in T1D and autoimmunity, generally ranging from 10-20%. The PoA for CNTY-813 reflects strong financing and execution signals that mitigate some modality risks, despite the absence of human data and Century's unproven status. Key risks associated with CNTY-813 include high technical challenges related to iPSC-derived islet engraftment, vascularization, and long-term function in humans. Additionally, there are concerns regarding potential immune evasion failures leading to rejection, manufacturing scalability, and consistency of potency for allogeneic cell therapy at a commercial scale. Upcoming catalysts include the IND submission in 2026 and initial Phase 1 clinical data in 2027. The investment thesis for CNTY-813 presents a high-risk, high-reward opportunity for a breakthrough in T1D treatment, warranting close monitoring of preclinical updates. Read More | Cell Therapies | Endocrine System |
Recent Updates
Recently added Catalysts
Century Therapeutics, Inc.$2.12
-0.01 (-0.7%)
D 30Pipeline Score Richly Valued Biotech · Commercial
Market Cap
407.60 M
EPS
-1.11
P/E Ratio
-
Value Trade
3.77 M
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
17.11 M
Operating CF
-25.26 M
Total Assets
326.55 M
Total Liabilities
61.81 M
Equity
264.74 M
D/E Ratio
12,345
-2.16 %
Week
-2.16 %
1 Month
6.6 %
3 Month
361.22 %
6 Month
-88.41 %
5 Year
-88.41 %
All Time
Cash Data
Cash Position
134.80 M
Monthly Burn
8.42 M
Runway
15.3 mo
Burn Trend
StableSEC Filing
May 13, 2026
Overview
Volume
272.86 K
52 Week Range
0.44 - 3.04
% held by Insiders
32.21 %
% held by Institutions
56.28 %
Enterprise Value
320.47 M
Total Shares
179.63 M
Short %
9.99 %
Float Shares
72.21 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D30
Pipeline Score $31M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.1x
rNPV / MCap Top 33%
Micro Cap (rank 607 of 905)
Percentile RankCentury Therapeutics, Inc. faces pipeline headwinds (30/100), with $143M risk-adjusted pipeline value, led by CNTY-101 in Systemic Lupus Erythematosus (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CNTY-101 Monoclonal antibody | Systemic Lupus Erythematosus | Phase 1 | NCT06255028 | 35% | $143M | ACTIVE NOT_RECRUITING | 6 | STALLED | C (44) | Aug 1, 2028 | HIGH_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
CNTY-101 | B-cell-mediated autoimmune diseases | Phase 1 | 2025-08-15 | |||
CNTY-101 | B-cell-mediated autoimmune diseases | Phase 1 | 2025-08-15 | |||
CNTY-101 | B-cell-mediated autoimmune diseases | Phase 1 | 2025-08-15 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IPSC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV 167.82 M (4,095.5%) | Shares Owned 74.75 M (1,758.53%) | Activity Avg Price $0 |
|---|---|---|---|---|
COMMODORE CAPITAL LP | 1.1 % | 19.65 M | 8.70 M | |
COMMODORE CAPITAL LP | 1.1 % | 19.65 M | 8.70 M | |
COMMODORE CAPITAL LP | 1.1 % | 19.65 M | 8.70 M |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
IPSC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IPSC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IPSC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IPSC Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
IPSC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0 | 0 | 0.00 | 0 | 0 | 0 | - | - | - | 3.74% | - | - |
| 2026-10-16 | 0 | 0 | 0.00 | 0 | 0 | 0 | - | - | - | 3.74% | - | - |
| 2026-10-16 | 0 | 0 | 0.00 | 0 | 0 | 0 | - | - | - | 3.74% | - | - |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| 0.05 | 2 | 34 | 2.5 | - | - | 0 |
| 0.05 | 2 | 34 | 2.5 | - | - | 0 |
| 0.05 | 2 | 34 | 2.5 | - | - | 0 |
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Century Therapeutics, Inc. (IPSC) News & Alerts
-
Demo Biotech Announces Positive Phase 3 Results
Competitive Position
How IPSC ranks across every disease it competes in| Indication | Rank | Phase | Best Drug | Top 3 Competitors | Market $B | LoA | Position |
|---|---|---|---|---|---|---|---|
| Lupus Nephritis | #16 of 17 | CNTY-101 + IL-2 + Lymphodepleting Chemotherapy | NVS VTRS AZN | $1.2B | 0.52 | ||
| Systemic Sclerosis | #18 of 21 | CNTY-101 + IL-2 + Lymphodepleting Chemotherapy | AZN BMY MRK | $2.68B | 0.52 | ||
| Systemic Lupus Erythematosus | #29 of 32 | CNTY-101 + IL-2 + Lymphodepleting Chemotherapy | BIIB VTRS BMY | $2.78B | 0.52 |